Regentis Biomaterials Ltd (RGNT)

Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement

HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE...

Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate

GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European...

Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon

Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoptionRenowned cartilage regeneration expert...

Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%

Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is...

Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update

$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial...

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair

Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product...

Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs

With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026New clinical sites to support engagement with leading orthopedic...

Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial

GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]